For this prospective observational study, 2.400 pregnant women of all weeks of pregnancy are recruited at nine study centres in the German region of Franconia. At baseline, general and pregnancy-associated diseases, history and prevalent COVID-19-typical symptoms and previous testing for SARS-CoV-2 infection are recorded. Nasopharyngeal swabs are collected for the determination of SARS-CoV-2 viral RNA as well as a blood sample for the evaluation of IgG antibody status by anti-SARS-CoV-2 ELISA. The primary outcome parameter is the rate of seropositive pregnancies in each of the three consecutive time cohorts. Secondary outcome parameters include prenatal, peripartum and postpartum maternal and neonatal morbidity.
8. February 2022
